{"entity":{"type":"insider","cik":"0001295913","url":"/insider/0001295913","json_url":"/insider/0001295913.json","name":"Saad Mark E","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":62,"n_filings":16,"first":"2004-11-22","last":"2026-01-02","span_basis":"filed_date"},"name_variants":[{"name":"Saad Mark E","source":"filing","n_filings":16,"first_seen":"2004-11-22","last_seen":"2026-01-02"}],"transactions":[{"id":6072322,"accession":"0001193125-26-001181","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001193125-26-001181","line_url":"/filing/0001193125-26-001181","is_derivative":false,"issuer_cik":"0001295913","issuer_name":"Axsome Therapeutics, Inc.","issuer_ticker":"AXSM","issuer_name_source":null,"issuer_url":"/issuer/0001295913","owner_cik":"0001295913","owner_name":"Saad Mark E","owner_display_name":"Saad Mark E","owner_url":"/insider/0001295913","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":37577.0,"shares_display":"37,577","price_per_share":165.18,"price_display":"165.18","price_state":"stated","total_value":6206968.86,"total_display":"6,206,968.86","total_whole":"6,206,969","shares_owned_after":10002.0,"shares_owned_after_display":"10,002","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-12-31","filed_date":"2026-01-02","scope":"insider","n_lines":2},{"id":4528185,"accession":"0000950170-25-113311","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-25-113311","line_url":"/filing/0000950170-25-113311#line-2","is_derivative":false,"issuer_cik":"0001295913","issuer_name":"Axsome Therapeutics, Inc.","issuer_ticker":"AXSM","issuer_name_source":null,"issuer_url":"/issuer/0001295913","owner_cik":"0001295913","owner_name":"Saad Mark E","owner_display_name":"Saad Mark E","owner_url":"/insider/0001295913","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9127.0,"shares_display":"9,127","price_per_share":125.07,"price_display":"125.07","price_state":"stated","total_value":1141513.89,"total_display":"1,141,513.89","total_whole":"1,141,514","shares_owned_after":10002.0,"shares_owned_after_display":"10,002","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-05","filed_date":"2025-09-05","scope":"insider"},{"id":2389330,"accession":"0000950170-24-105616","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-105616","line_url":"/filing/0000950170-24-105616#line-2","is_derivative":false,"issuer_cik":"0001295913","issuer_name":"Axsome Therapeutics, Inc.","issuer_ticker":"AXSM","issuer_name_source":null,"issuer_url":"/issuer/0001295913","owner_cik":"0001295913","owner_name":"Saad Mark E","owner_display_name":"Saad Mark E","owner_url":"/insider/0001295913","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11016.0,"shares_display":"11,016","price_per_share":91.31,"price_display":"91.31","price_state":"stated","total_value":1005870.96,"total_display":"1,005,870.96","total_whole":"1,005,871","shares_owned_after":10002.0,"shares_owned_after_display":"10,002","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-11","filed_date":"2024-09-11","scope":"insider"},{"id":4678413,"accession":"0001209191-21-065696","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-21-065696","line_url":"/filing/0001209191-21-065696","is_derivative":false,"issuer_cik":"0001295913","issuer_name":"Axsome Therapeutics, Inc.","issuer_ticker":"AXSM","issuer_name_source":null,"issuer_url":"/issuer/0001295913","owner_cik":"0001295913","owner_name":"Saad Mark E","owner_display_name":"Saad Mark E","owner_url":"/insider/0001295913","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3300.0,"shares_display":"3,300","price_per_share":34.521727272727276,"price_display":"34.52","price_state":"stated","total_value":113921.7,"total_display":"113,921.70","total_whole":"113,922","shares_owned_after":10002.0,"shares_owned_after_display":"10,002","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-11-17","filed_date":"2021-11-19","scope":"insider","n_lines":4},{"id":8134219,"accession":"0001179110-19-006616","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001179110-19-006616","line_url":"/filing/0001179110-19-006616#line-1","is_derivative":false,"issuer_cik":"0001295913","issuer_name":"Axsome Therapeutics, Inc.","issuer_ticker":"AXSM","issuer_name_source":null,"issuer_url":"/issuer/0001295913","owner_cik":"0001295913","owner_name":"Saad Mark E","owner_display_name":"Saad Mark E","owner_url":"/insider/0001295913","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3500.0,"shares_display":"3,500","price_per_share":22.33,"price_display":"22.33","price_state":"stated","total_value":78155.0,"total_display":"78,155.00","total_whole":"78,155","shares_owned_after":7002.0,"shares_owned_after_display":"7,002","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-05-23","filed_date":"2019-05-24","scope":"insider"},{"id":3549453,"accession":"0001140361-12-015618","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-12-015618","line_url":"/filing/0001140361-12-015618","is_derivative":false,"issuer_cik":"0001095981","issuer_name":"CYTORI THERAPEUTICS, INC.","issuer_ticker":"CYTX","issuer_name_source":null,"issuer_url":"/issuer/0001095981","owner_cik":"0001295913","owner_name":"Saad Mark E","owner_display_name":"Saad Mark E","owner_url":"/insider/0001295913","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":2.5494,"price_display":"2.55","price_state":"stated","total_value":25494.0,"total_display":"25,494.00","total_whole":"25,494","shares_owned_after":151900.0,"shares_owned_after_display":"151,900","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-03-14","filed_date":"2012-03-14","scope":"insider","n_lines":2},{"id":9110174,"accession":"0001140361-11-041464","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001140361-11-041464","line_url":"/filing/0001140361-11-041464","is_derivative":false,"issuer_cik":"0001095981","issuer_name":"CYTORI THERAPEUTICS, INC.","issuer_ticker":"CYTX","issuer_name_source":null,"issuer_url":"/issuer/0001095981","owner_cik":"0001295913","owner_name":"Saad Mark E","owner_display_name":"Saad Mark E","owner_url":"/insider/0001295913","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6500.0,"shares_display":"6,500","price_per_share":3.1215384615384614,"price_display":"3.12","price_state":"stated","total_value":20290.0,"total_display":"20,290.00","total_whole":"20,290","shares_owned_after":122500.0,"shares_owned_after_display":"122,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2011-08-12","filed_date":"2011-08-12","scope":"insider","n_lines":4},{"id":7662611,"accession":"0001140361-10-022618","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001140361-10-022618","line_url":"/filing/0001140361-10-022618","is_derivative":false,"issuer_cik":"0001095981","issuer_name":"CYTORI THERAPEUTICS, INC.","issuer_ticker":"CYTX","issuer_name_source":null,"issuer_url":"/issuer/0001095981","owner_cik":"0001295913","owner_name":"Saad Mark E","owner_display_name":"Saad Mark E","owner_url":"/insider/0001295913","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6000.0,"shares_display":"6,000","price_per_share":4.290166666666667,"price_display":"4.29","price_state":"stated","total_value":25741.0,"total_display":"25,741.00","total_whole":"25,741","shares_owned_after":81500.0,"shares_owned_after_display":"81,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2010-05-21","filed_date":"2010-05-21","scope":"insider","n_lines":3},{"id":3537679,"accession":"0001140361-08-019037","txn_seq":13,"anchor":"line-13","filing_url":"/filing/0001140361-08-019037","line_url":"/filing/0001140361-08-019037","is_derivative":false,"issuer_cik":"0001095981","issuer_name":"CYTORI THERAPEUTICS, INC.","issuer_ticker":"CYTX","issuer_name_source":null,"issuer_url":"/issuer/0001095981","owner_cik":"0001295913","owner_name":"Saad Mark E","owner_display_name":"Saad Mark E","owner_url":"/insider/0001295913","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":15000.0,"shares_display":"15,000","price_per_share":6.687349466666666,"price_display":"6.69","price_state":"stated","total_value":100310.242,"total_display":"100,310.24","total_whole":"100,310","shares_owned_after":66845.0,"shares_owned_after_display":"66,845","ownership_form":"D","is_10b5_1":null,"transaction_date":"2008-08-12","filed_date":"2008-08-12","scope":"insider","n_lines":13},{"id":5447007,"accession":"0001295913-06-000007","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001295913-06-000007","line_url":"/filing/0001295913-06-000007","is_derivative":false,"issuer_cik":"0001095981","issuer_name":"CYTORI THERAPEUTICS, INC.","issuer_ticker":"CYTX","issuer_name_source":null,"issuer_url":"/issuer/0001095981","owner_cik":"0001295913","owner_name":"Saad Mark E","owner_display_name":"Saad Mark E","owner_url":"/insider/0001295913","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1850.0,"shares_display":"1,850","price_per_share":5.077297297297298,"price_display":"5.08","price_state":"stated","total_value":9393.0,"total_display":"9,393.00","total_whole":"9,393","shares_owned_after":61500.0,"shares_owned_after_display":"61,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2006-09-05","filed_date":"2006-09-07","scope":"insider","n_lines":2},{"id":5291028,"accession":"0001295913-06-000006","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001295913-06-000006","line_url":"/filing/0001295913-06-000006","is_derivative":false,"issuer_cik":"0001095981","issuer_name":"CYTORI THERAPEUTICS, INC.","issuer_ticker":"CYTX","issuer_name_source":null,"issuer_url":"/issuer/0001095981","owner_cik":"0001295913","owner_name":"Saad Mark E","owner_display_name":"Saad Mark E","owner_url":"/insider/0001295913","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1550.0,"shares_display":"1,550","price_per_share":5.308709677419355,"price_display":"5.31","price_state":"stated","total_value":8228.5,"total_display":"8,228.50","total_whole":"8,229","shares_owned_after":59350.0,"shares_owned_after_display":"59,350","ownership_form":"D","is_10b5_1":null,"transaction_date":"2006-09-01","filed_date":"2006-09-05","scope":"insider","n_lines":5},{"id":5291010,"accession":"0001295913-06-000006","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001295913-06-000006","line_url":"/filing/0001295913-06-000006","is_derivative":false,"issuer_cik":"0001095981","issuer_name":"CYTORI THERAPEUTICS, INC.","issuer_ticker":"CYTX","issuer_name_source":null,"issuer_url":"/issuer/0001095981","owner_cik":"0001295913","owner_name":"Saad Mark E","owner_display_name":"Saad Mark E","owner_url":"/insider/0001295913","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":750.0,"shares_display":"750","price_per_share":5.483333333333333,"price_display":"5.48","price_state":"stated","total_value":4112.5,"total_display":"4,112.50","total_whole":"4,113","shares_owned_after":58100.0,"shares_owned_after_display":"58,100","ownership_form":"D","is_10b5_1":null,"transaction_date":"2006-08-31","filed_date":"2006-09-05","scope":"insider","n_lines":2},{"id":3622441,"accession":"0001295913-06-000005","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001295913-06-000005","line_url":"/filing/0001295913-06-000005","is_derivative":false,"issuer_cik":"0001095981","issuer_name":"CYTORI THERAPEUTICS, INC.","issuer_ticker":"CYTX","issuer_name_source":null,"issuer_url":"/issuer/0001095981","owner_cik":"0001295913","owner_name":"Saad Mark E","owner_display_name":"Saad Mark E","owner_url":"/insider/0001295913","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":750.0,"shares_display":"750","price_per_share":5.423333333333333,"price_display":"5.42","price_state":"stated","total_value":4067.5,"total_display":"4,067.50","total_whole":"4,068","shares_owned_after":57350.0,"shares_owned_after_display":"57,350","ownership_form":"D","is_10b5_1":null,"transaction_date":"2006-08-30","filed_date":"2006-08-30","scope":"insider","n_lines":3},{"id":3622435,"accession":"0001295913-06-000005","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001295913-06-000005","line_url":"/filing/0001295913-06-000005","is_derivative":false,"issuer_cik":"0001095981","issuer_name":"CYTORI THERAPEUTICS, INC.","issuer_ticker":"CYTX","issuer_name_source":null,"issuer_url":"/issuer/0001095981","owner_cik":"0001295913","owner_name":"Saad Mark E","owner_display_name":"Saad Mark E","owner_url":"/insider/0001295913","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":800.0,"shares_display":"800","price_per_share":5.210625,"price_display":"5.21","price_state":"stated","total_value":4168.5,"total_display":"4,168.50","total_whole":"4,169","shares_owned_after":56100.0,"shares_owned_after_display":"56,100","ownership_form":"D","is_10b5_1":null,"transaction_date":"2006-08-29","filed_date":"2006-08-30","scope":"insider","n_lines":4},{"id":4847640,"accession":"0001295913-06-000004","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001295913-06-000004","line_url":"/filing/0001295913-06-000004#line-5","is_derivative":false,"issuer_cik":"0001095981","issuer_name":"CYTORI THERAPEUTICS, INC.","issuer_ticker":"CYTX","issuer_name_source":null,"issuer_url":"/issuer/0001095981","owner_cik":"0001295913","owner_name":"Saad Mark E","owner_display_name":"Saad Mark E","owner_url":"/insider/0001295913","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":800.0,"shares_display":"800","price_per_share":5.197,"price_display":"5.20","price_state":"stated","total_value":4157.6,"total_display":"4,157.60","total_whole":"4,158","shares_owned_after":55800.0,"shares_owned_after_display":"55,800","ownership_form":"D","is_10b5_1":null,"transaction_date":"2006-08-28","filed_date":"2006-08-28","scope":"insider"},{"id":4847635,"accession":"0001295913-06-000004","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001295913-06-000004","line_url":"/filing/0001295913-06-000004#line-4","is_derivative":false,"issuer_cik":"0001095981","issuer_name":"CYTORI THERAPEUTICS, INC.","issuer_ticker":"CYTX","issuer_name_source":null,"issuer_url":"/issuer/0001095981","owner_cik":"0001295913","owner_name":"Saad Mark E","owner_display_name":"Saad Mark E","owner_url":"/insider/0001295913","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":200.0,"shares_display":"200","price_per_share":5.0,"price_display":"5.00","price_state":"stated","total_value":1000.0,"total_display":"1,000.00","total_whole":"1,000","shares_owned_after":55000.0,"shares_owned_after_display":"55,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2006-08-25","filed_date":"2006-08-28","scope":"insider"},{"id":4847629,"accession":"0001295913-06-000004","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001295913-06-000004","line_url":"/filing/0001295913-06-000004#line-3","is_derivative":false,"issuer_cik":"0001095981","issuer_name":"CYTORI THERAPEUTICS, INC.","issuer_ticker":"CYTX","issuer_name_source":null,"issuer_url":"/issuer/0001095981","owner_cik":"0001295913","owner_name":"Saad Mark E","owner_display_name":"Saad Mark E","owner_url":"/insider/0001295913","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":200.0,"shares_display":"200","price_per_share":5.0,"price_display":"5.00","price_state":"stated","total_value":1000.0,"total_display":"1,000.00","total_whole":"1,000","shares_owned_after":54800.0,"shares_owned_after_display":"54,800","ownership_form":"D","is_10b5_1":null,"transaction_date":"2006-08-25","filed_date":"2006-08-28","scope":"insider"}],"collapsed":true,"next_cursor":"2006-08-25|4847629","ledger_fault":false,"count":{"value":62,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":58,"open_market":true},{"code":"S","label":"Open-market sale","n":4,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":62},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001579428","name":"Axsome Therapeutics, Inc.","url":"/issuer/0001579428","role":"Director","n_filings":5,"first_seen":"2019-05-24","last_seen":"2026-01-02"},{"type":"issuer","type_label":"ISSUER","cik":"0001095981","name":"CYTORI THERAPEUTICS, INC.","url":"/issuer/0001095981","role":"Officer (Chief Financial Officer)","n_filings":11,"first_seen":"2004-11-22","last_seen":"2012-03-14"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001295913","retrieved_at":"2026-08-23T15:17:25+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}